Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma

Biomark Med. 2019 May;13(7):545-555. doi: 10.2217/bmm-2018-0414. Epub 2019 May 29.

Abstract

Aim: To evaluate the diagnostic performance of serum AFU for early stage hepatocellular carcinoma (HCC). Methods: Concentration of AFU and AFP were measured in 512 patients. The performance was compared for AFU and AFP alone or in combination. Results: The area under the curve (AUC) for AFU was 0.68, with a sensitivity of 56.1% and specificity of 69.2% at the cut-off value of 24 U/l; whereas the AUC for AFP was 0.83, with a sensitivity of 58.2% and specificity of 85.2% at cut-off value of 20 ng/ml. The AUC of AFU alone or the combination with AFP were lower than that of AFP alone. Conclusion: AFU is a suboptimal biomarker for early detection of HCC.

Keywords: area under the curve; biomarker; diagnostic performance; early detection; early stage-HCC; hepatocellular carcinoma; sensitivity; specificity; α-L-fucosidase; α-fetoprotein.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular / blood
  • Carcinoma, Hepatocellular / diagnosis*
  • Carcinoma, Hepatocellular / enzymology*
  • Carcinoma, Hepatocellular / pathology
  • Early Detection of Cancer*
  • Female
  • Humans
  • Liver Neoplasms / blood
  • Liver Neoplasms / diagnosis*
  • Liver Neoplasms / enzymology*
  • Liver Neoplasms / pathology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Tumor Burden
  • Young Adult
  • alpha-Fetoproteins / metabolism
  • alpha-L-Fucosidase / blood*

Substances

  • alpha-Fetoproteins
  • alpha-L-Fucosidase